A COX2-targeting cancer-specific fluorescent probe for hydrogen sulfide detection in living cells, , and zebrafish

A novel cyclooxygenase-2 (COX-2) targeted H 2 S-activated cancer-specific fluorescent probe, namely, COX2-H 2 S , was designed and synthesized, with naphthalimide as the fluorophore and indomethacin as the targeting group. This H 2 S-sensing probe was developed to differentiate tumor cells from norm...

Full description

Saved in:
Bibliographic Details
Published inAnalyst (London) Vol. 149; no. 5; pp. 1489 - 1495
Main Authors Yuan, Fengying, Zhao, Qiao, Zeng, Yanyan, Liao, Xu Fang, Li, Jiali, Liu, Bo, Kou, Jun Feng, Zhong, Xiaolin, Wu, Xiang Hua, Zhang, Jun Feng, Ren, Wen Xiu
Format Journal Article
Published 26.02.2024
Online AccessGet full text

Cover

Loading…
More Information
Summary:A novel cyclooxygenase-2 (COX-2) targeted H 2 S-activated cancer-specific fluorescent probe, namely, COX2-H 2 S , was designed and synthesized, with naphthalimide as the fluorophore and indomethacin as the targeting group. This H 2 S-sensing probe was developed to differentiate tumor cells from normal cells and was tested in living cells, Caenorhabditis elegans ( C. elegans ), and zebrafish. The probe could successfully be used for imaging endogenous and exogenous H 2 S in living cells, demonstrating high sensitivity and specificity and strong anti-interference. COX2-H 2 S had the ability to not only discern cancer cells from normal cells but also specifically recognize 9L/lacZ cells from other glioblastoma cells (U87-MG and LN229). It could also be successfully applied for the fluorescent live imaging of H 2 S in both C. elegans and zebrafish. A novel H 2 S-activated cancer-specific fluorescent probe COX2-H 2 S was rationally developed, with naphthalimide as the fluorophore and indomethacin as the targeting unit, for the imaging determination of H 2 S in living cells, C. elegans , and zebrafish.
Bibliography:https://doi.org/10.1039/d3an01847d
Electronic supplementary information (ESI) available. See DOI
ISSN:0003-2654
1364-5528
DOI:10.1039/d3an01847d